DNTH 28.48 Dianthus Therapeutics, Inc.
| Range: | 6.58-33.77 | Vol Avg: | 201756 | Last Div: | 0 | Changes: | -0.82 |
| Beta: | 0 | Cap: | 0.81B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jun 21 2018 | Empoloyees: | 53 | ||
| CUSIP: | 252828108 | CIK: | 0001690585 | ISIN: | US2528281080 | Country: | US |
| CEO: | Mr. Marino Garcia M.B.A. | Website: | https://dianthustx.com | ||||
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow